financetom
Business
financetom
/
Business
/
Cafe chain Black Rock Coffee Bar targets $861 million valuation in rare US consumer IPO
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cafe chain Black Rock Coffee Bar targets $861 million valuation in rare US consumer IPO
Sep 2, 2025 4:49 AM

Sept 2 (Reuters) - Black Rock Coffee Bar is targeting a

valuation of up to $860.7 million in its New York initial public

offering, the cafe chain said on Tuesday, setting the stage for

a rare consumer sector listing amid an IPO market buoyed by

tech-heavy debuts.

The Scottsdale, Arizona-based company is seeking up to $265

million by offering 14.7 million shares priced between $16 and

$18 apiece.

While the new listings market has made a comeback after a

brief pause in April, consumer-related IPOs have been a key

miss, with much of the activity coming from sectors with

low-tariff exposure.

Black Rock Coffee's flotation will be a crucial test of

investor appetite for consumer IPOs, with its peer Dutch Bros ( BROS )

having gone public back in 2021.

Founded in 2008, Black Rock Coffee is a founder-owned

operator of drive-thru coffee bars, selling hot and iced coffees

as well as energy drinks, including Nitro Cold Brew and Caramel

Blondie.

While it began as a single coffee stand in Oregon, it has

since bulked up with over 150 locations spanning seven states

from the Pacific Northwest to Texas.

BEANS AND TARIFFS

The company sources most of its coffee beans from Brazil,

Ethiopia, Colombia and Mexico, among other countries.

Inflated costs or lower availability of arabica coffee

beans, dairy and other commodities could have an adverse impact

on its business, according to its prospectus.

Coffee prices have hit a record high this year, driven by

droughts in top producers Brazil and Vietnam and a U.S. move to

impose 50% duties on beans imported from Brazil.

Moving forward, the company expects much of the tariff

exposure stemming from refrigeration units, espresso machines

and coffee beans.

Black Rock Coffee will list on the Nasdaq under the symbol

"BRCB". J.P. Morgan, Jefferies, Morgan Stanley and Baird are the

lead underwriters for the offering.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
TE Connectivity Changes Place of Incorporation to Ireland
TE Connectivity Changes Place of Incorporation to Ireland
Oct 2, 2024
07:38 AM EDT, 09/30/2024 (MT Newswires) -- TE Connectivity ( TEL ) said Monday it has completed the change in the place of its incorporation to Ireland from Switzerland. The company said it will continue to trade on the New York Stock Exchange under the TEL symbol. As part of the change, each shareholder of TE Connectivity ( TEL )...
BRIEF-Marsh Mclennan to Acquire Mcgriff Insurance Services
BRIEF-Marsh Mclennan to Acquire Mcgriff Insurance Services
Oct 2, 2024
Sept 30 (Reuters) - Marsh & McLennan Companies Inc ( MMC ) : * MARSH MCLENNAN TO ACQUIRE MCGRIFF INSURANCE SERVICES * MARSH & MCLENNAN ( MMC ) - UNDER TERMS OF TRANSACTION, MARSH MCLENNAN WILL PAY $7.75 BILLION IN CASH CONSIDERATION * MARSH & MCLENNAN COMPANIES INC ( MMC ) - TO ASSUME $500 MILLION DEFERRED TAX ASSET Source...
BioCryst Awarded 5-Year US Influenza Contract Worth up to $69 Million
BioCryst Awarded 5-Year US Influenza Contract Worth up to $69 Million
Oct 2, 2024
07:38 AM EDT, 09/30/2024 (MT Newswires) -- BioCryst Pharmaceuticals ( BCRX ) said Monday it has been awarded a US Department of Health and Human Services contract worth up to $69 million over five years to provide up to 95,625 doses of Rapivab for the treatment of influenza. Under the contract, BioCryst will supply injections to the Center for the...
Precision BioSciences Submits Clinical Trial Applications for Hepatitis B Treatment
Precision BioSciences Submits Clinical Trial Applications for Hepatitis B Treatment
Oct 2, 2024
07:40 AM EDT, 09/30/2024 (MT Newswires) -- Precision BioSciences ( DTIL ) said Monday it submitted clinical trial applications to initiate a phase 1 study to evaluate PBGENE-HBV, its investigative treatment for chronic hepatitis B. The company said it is expects to begin a phase 1 study soon and to report results next year. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved